Merck, Schering Suspend TV Ads Touting Vytorin

By Erin Marie Daly

Law360, New York (January 23, 2008, 12:00 AM ET) -- Merck & Co. and Schering-Plough Corp. are yanking television ads for Vytorin amid proposed class actions and a congressional inquiry on the effectiveness of the cholesterol drug.

The companies said Tuesday that they had decided to voluntarily and temporarily suspend direct-to-consumer broadcast advertising of Vytorin, which combines Zetia and Zocor, the Associated Press reported.

The decision came in the wake of public outcry after a study showed last week that Vytorin is not more effective than Zocor at reducing fat deposits in arteries. Zocor is Merck’s...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles